BiotechTube
Home/Oxeia Biopharmaceuticals/Dr. Michael Wyand
DM

Dr. Michael Wyand

Chief Executive Officer

Oxeia Biopharmaceuticals

Therapeutic Areas

NeurologyTraumatic Brain Injury

Oxeia Biopharmaceuticals Pipeline

DrugIndicationPhase
OXE103Persistent Concussion Symptoms (Post-Concussion Syndrome)Phase 2b (Planned)